Jeffrey Browning
43Patents
15h-index
28Co-inventors
81Inventor score
Filing activity: Mar 13, 1991 → May 15, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7083785B2 | Methods of treatment by administering an anti-BCMA antibody | Chemistry; Metallurgy | 86 | Expired |
| US5925351A | Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease | Emerging Cross-Sectional Technologies | 39 | Expired |
| US6869605B2 | BAFF, inhibitors thereof and their use in the modulation of B-cell response | Human Necessities | 32 | Expired |
| US6312691A | Lymphotoxin-.alpha./.beta. complexes and anti-lympotoxin-.beta. receptor antibodies as anti-tumor agents | Emerging Cross-Sectional Technologies | 26 | Expired |
| US6403087B1 | Soluble lymphotoxin-&bgr; receptors as therapeutic agents for the treatment of immunological disease | Emerging Cross-Sectional Technologies | 25 | Expired |
| US7001598B2 | Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents | Emerging Cross-Sectional Technologies | 24 | Expired |
| US6669941B1 | Soluble lymphotoxin-&bgr; receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease | Emerging Cross-Sectional Technologies | 23 | Expired |
| US5661004A | Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof | Human Necessities | 22 | Expired |
| US5795964A | Lymphotoxin-beta and lymphotoxin-beta complexes | Human Necessities | 21 | Expired |
| US5670149A | Lymphotoxin-.beta., Lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof | Human Necessities | 21 | Expired |
| US7030080B2 | Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof | Chemistry; Metallurgy | 21 | Expired |
| US7799902B2 | Receptor coupling agents and compositions thereof | Physics | 21 | Active |
| US7208151B2 | Tweak receptor agonists as anti-angiogenic agents | Chemistry; Metallurgy | 19 | Expired |
| US7060667B1 | Treatment of follicular lymphomas using inhibitors of the LT pathway | Human Necessities | 18 | Expired |
| US7566769B2 | Tumor necrosis factor related ligand | Chemistry; Metallurgy | 16 | Active |
| US7109298B2 | Tumor necrosis factor related ligand | Chemistry; Metallurgy | 13 | Expired |
| US7129061B1 | Tumor necrosis factor related ligand | Chemistry; Metallurgy | 12 | Expired |
| US7255854B1 | Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases | Emerging Cross-Sectional Technologies | 12 | Expired |
| US7087725B2 | Antibodies specifically reactive with a tumor necrosis factor related ligand | Chemistry; Metallurgy | 12 | Expired |
| US5484711A | DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VI | Human Necessities | 11 | Expired |
| US7846438B2 | Methods of promoting neurite outgrowth with soluble TAJ polypeptides | Physics | 7 | Active |
| US7695934B2 | Tumor necrosis factor related ligand | Chemistry; Metallurgy | 7 | Active |
| US5298489A | DNA sequences recombinant DNA molecules and processes for producing lipocortins III, IV, V and VI | Human Necessities | 7 | Expired |
| US7309492B2 | Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of systemic lupus erythematosus | Emerging Cross-Sectional Technologies | 7 | Expired |
| US7731963B2 | TWEAK receptor agonists as anti-angiogenic agents | Chemistry; Metallurgy | 7 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.